The non-essential amino acid glycine is a signalling molecule that has two physiological functions in the central nervous system (CNS) (FIG. 1) . As an inhibitory neurotransmitter, glycine directly activates ionotropic glycine receptors (which contain heteromeric α1β, α2β or α3β subunit combinations) that are found predominantly at inhibitory synapses in the spinal cord, brainstem and retina. Glycine that is released from presynaptic nerve terminals binds to the strychnine-sensitive glycine-A binding site on glycine receptors and activates the influx of chloride ions through an integral anion channel, which leads to the hyperpolarization of the postsynaptic membrane. This fast neuronal inhibition is the predominant function of glycine receptor activation in the adult brain. However, the activation of extrasynaptic excitatory glycine receptors containing the α2 subunit (GlyRα2) controls the migration of interneurons by activating voltage-gated calcium channels. This modulates actomyosin contractility and controls the tangential migration of cortical neurons during embryogenesis . The binding of glycine to the strychnine-insensitive glycine-B site located on the NR1 subunit common to all NMDA receptors is a pre-requisite for NMDA receptor activation by the endogenous neurotransmitter l-glutamate. Glycine, therefore, further functions as a positive allosteric modulator of calcium-dependent neuronal excitation and neural plasticity that is mediated by NMDA receptors throughout the CNS.
The extracellular levels of glycine at inhibitory and excitatory synapses are controlled by glycine transporters (GlyTs) 3, 4 . Both subtypes, GlyT1 and GlyT2, belong to the sodium-dependent solute carrier family 6 (SLC6) of transporters but they have different regional and cellular expression patterns in the CNS (FIG. 2) , different stoi chiometries (that is, the number of sodium ions that are co-transported with every glycine molecule) and varying abilities to reverse-transport glycine into the extracellular space 5, 6 . To date, five variants of GlyT1 (GlyT1a, GlyT1b, GlyT1c, GlyT1d and GlyT1e) and three variants of GlyT2 (GlyT2a, GlyT2b and GlyT2c) that occur as a result of alternative promoter usage and/or splicing have been identified, but the relative distributions of these within the CNS have not been fully characterized.
Data from knockout mouse models show that constitutive disruption of GlyT1 or GlyT2 is lethal 7, 8 , primarily as a result of excessive or deficient glycinergic inhibition, respectively. The loss of GlyT1 expressed on astrocytes severely disrupts the clearance of glycine that is released into synaptic clefts, which leads to sustained inhibition of respiratory centres in the brainstem in early postnatal life 9 . The loss of presynaptic GlyT2 drastically curtails the refilling of presynaptic glycine vesicles and severely disrupts neurotransmission 6, 10 . However, the disruption of GlyT1 in adult animals 9 , or restricting the disruption of GlyT1 to the brain during perinatal life 11, 12 , is not lethal. Genetic defects in human GlyT2 (encoded by SLC6A5) are known to cause startle disease (also known as hyperekplexia) 13, 14 but the involvement of GlyT1 defects in glycine encephalopathy (also known as non-ketotic hyperglycinaemia) is not as clear-cut
.
Regulation of glycinergic inhibitory neurotransmission clearly requires the coordinated activities of GlyT1 and GlyT2, and both transporters are potential targets for manipulating glycinergic neurotransmission. GlyT1 is the primary regulator of glycine availability near NMDA receptors and is located at neuronal presynaptic and postsynaptic sites of glutamatergic synapses 15, 16 and on neighbouring astrocytes 17 . GlyT1 is essential for maintaining the concentration of extracellular glycine near excitatory a | Glycine transporter 1 (GlyT1) and GlyT2 both contribute to the control of extracellular glycine levels at inhibitory glycinergic synapses, and they also limit the spillover of glycine to neighbouring synapses. GlyT2 maintains a high concentration of glycine in presynaptic terminals, and glycine that is recycled via GlyT2 appears to be the sole source of releasable glycine. Glycine is transported into presynaptic vesicles by the vesicular inhibitory amino acid transporter (VIAAT). The less energetic coupling of GlyT1 may allow glycine to shuttle between astrocytes and neurons, thus maximizing the recycling of released glycine by GlyT2. Inhibition of GlyT2 may thus weaken glycinergic inhibitory neurotransmission as a result of impaired vesicular refilling at the presynaptic terminal. However, this does not apply to the regulation of pain signals in the dorsal horn of the spinal cord, where inhibition of GlyT2 (in the same way as GlyT1) potentiates glycinergic signalling at the postsynaptic interface by reducing the clearance of the released glycine. b | At glutamatergic synapses that express NMDA (N-methyl-d-aspartate) receptors, GlyT1 found at the pre-and postsynaptic terminals as well as in neighbouring glial cells contributes to the lowering of extracellular glycine concentration at the synaptic cleft to below the level that is required to saturate the co-agonist site (the glycine-B site), even though glycine concentrations in the cerebrospinal fluid (CSF) remain high. c | Inhibition of GlyT1 function may elevate the baseline occupancy of the glycine-B site, which is a prerequisite for NMDA receptor activation upon release of l-glutamate from the presynaptic terminal, and therefore increase the probability of NMDA receptor responses. 
Affects
The experience and expression of feelings or emotions that can be positive or negative; the psychological processes involved are often contrasted with (but cannot be entirely disentangled from) cognition and thought processes.
Executive functions
A broad number of cognitive processes including planning, working memory, attention, problem solving, reasoning, inhibition, mental flexibility and task switching, as well as the initiation and monitoring of these cognitive processes.
synapses at sufficiently low levels to prevent the saturation of the glycine-B site on NMDA receptors. By limiting the occupancy of the glycine-B site, GlyT1-mediated glycine reuptake effectively regulates the activation of NMDA receptors under physiological conditions. Importantly, the elevated binding to glycine-B sites that occurs as a result of GlyT1 inhibition would only increase the probability of NMDA receptor activation under specific preconditions -namely, when the magnesium-mediated blockade of the NMDA receptor has been released by prior depolarization owing to AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor activation (FIG. 1) . This would result in an 'on-demand' facilitation of NMDA receptor activation that is physiologically distinct from the effects of direct NMDA receptor agonists. This unique mode of intervention on NMDA receptors could be beneficial in clinical conditions in which deficient NMDA receptor signalling is strongly implicated, such as schizophrenia. Indeed, the clinical development of selective GlyT1 inhibitors is most advanced in this indication. If clinical trials of GlyT1 inhibitors in schizophrenia are successful, this indication would be the first disease to benefit from this novel pharmacological approach.
Given that GlyTs act as homeostatic regulators of glycine levels in the CNS and therefore control the balance of neuronal excitation and inhibition within several neural circuits (FIG. 1) , the application of GlyT-based pharmacotherapy has been suggested for many disorders besides schizophrenia. These include pain control, alcohol and drug dependence, depression, epilepsy and obsessivecompulsive disorders, as well as anxiety disorders, memory deficits, Parkinson's disease and autism.
In this Review, we examine the clinical and preclinical data as well as the mechanistic models that support the therapeutic potential of GlyT inhibition in schizophrenia, alcohol dependence and pain -three conditions in which rebalancing glycine homeostasis in specific CNS regions is expected to alleviate clinical symptoms. For example, GlyT inhibition in the forebrain has beneficial effects in patients with schizophrenia, whereas in individuals with alcohol dependence this strategy targets reward circuits that are centred on the ventral tegmental area in the midbrain. In pain, effective modulation of glycine homeostasis can suppress pain signals in the dorsal horn. In addition, we highlight the potential use of glycine reuptake inhibition as a novel strategy in other neuropsychiatric conditions in which the precise therapeutic mechanisms remain to be clarified. Last, possible strategies to improve therapeutic efficacy and symptom specificity are explored.
Therapeutic potential of GlyT1 in schizophrenia Current anti-schizophrenia medications that result in dopamine receptor blockade can suppress positive symptoms, such as hallucinations and delusions, but they are largely ineffective against negative and cognitive symptoms that include persistent deficits in affects, memory and executive functions 18 . It is currently thought that the negative and cognitive symptoms of schizophrenia are due to deficient glutamate signalling via NMDA receptors 19, 20 and it has been suggested that pharmacotherapy based on the augmentation of NMDA receptor function could be beneficial. However, NMDA receptor agonists cause seizures, cell death and other serious neurotoxic side effects 21 . The search for alternative therapeutic . Immunoreactivity was visualized by immunoperoxidase staining in parasagittal sections and displayed in pseudocolours. The scale was adjusted separately for each image to maximize the regional differences in staining intensity (ranging from dark blue for the background to white for maximal intensity). Note that, as expected, EGFP immunoreactivity and GlyT2 immunoreactivity exhibit similar distribution patterns, although the signal-to-noise ratio is higher for EGFP. By contrast, glycine immunoreactivity has a more widespread distribution, notably in the forebrain, whereas GlyT1 immunoreactivity overlaps only partially with EGFP, showing an intense uniform distribution in the diencephalon. 
Positive allosteric modulatory sites
Binding sites on a receptor or channel that are distinct from the active site. These sites allow regulatory ligands (that have an affinity to these sites) to enhance the biochemical response that is associated with the activation of the active site.
Glutamate hypothesis
A hypothesis of the patho physiology of schizophrenia that attributes the production of schizophrenia symptoms to the underactivity of the glutamatergic neuro transmission systemin particular, to the transmission of neural signals via NMDA (N-methyl-d-aspartate) receptors.
Glyt1
+/− mice routes has centred on the positive allosteric modulatory sites of the NMDA receptor, such as the glycine-B site 22 . The glycine-B site is not saturated under physiological conditions 23 , so increasing its occupancy should augment NMDA receptor excitability in a way that is contingent upon glutamate release from presynaptic nerve terminals. This would minimize the excitotoxicity that is associated with direct NMDA receptor agonists.
However, attempts to increase levels of the two endogenous ligands for the glycine-B site -glycine and d-serine -in the brain through dietary supplements require very high doses to overcome rapid metabolism and the blood-brain barrier, which prevents their entry into the brain. Moreover, given that glycine and d-serine are amino acids that are involved in many biochemical pathways, the dietary approach could also result in side effects. It is also difficult to design compounds that selectively mimic the action of small molecules such as glycine and d-serine on the glycine-B site owing to constraints over possible modifications to their backbone structures 24 . So, inhibiting glycine reuptake -in particular, GlyT1-mediated reuptake in the vicinity of NMDA receptors (FIG. 1) -emerges as a rational alternative for elevating the occupancy of the glycine-B site 25 . Among existing synthetic GlyT1 inhibitors 26 (TABLE 1) , bitopertin (also known as RG1678 and RO4917838) is the most advanced in development (currently in Phase III clinical trials; ClinicalTrials.gov identifiers: NCT01192867, NCT01192906, NCT01192880, NCT01235520 and NCT01235559). This drug could represent the first successful translation of the glutamate hypothesis since the inception of this theory 30 years ago, and would represent the third generation of anti-schizophrenia drugs.
Preclinical models. Several genetically modified mice lacking the gene encoding GlyT1 have been used to assess the potential of GlyT1 inhibition in controlling schizophrenia-related behavioural and cognitive deficits 27 . Constitutive heterozygous GlyT1-knockout mice (Glyt1 +/-mice) are viable, but their initial characterization was disappointing 28 , possibly owing to concomitant structural and functional compensations at the glutamatergic synapses in this mutant line 29, 30 . Subsequently,
fl/fl :CamKIIα-Cre +/-conditional knockout mice were generated to specifically target neuronal GlyT1 in the forebrain -an area of the brain in which augmentation of NMDA receptor function is hypothesized to produce anti-schizophrenia effects 11 . These mice had clear schizophrenia-resilient phenotypes. Although data obtained from these mice were not entirely free from interpretative difficulties owing to potential developmental compensation, comparisons with other conditional gene knockout models as well as pharmacological inhibition of GlyT1 in wild-type animals have revealed more in-depth insights Box 1 | Glycine transporters in glycine encephalopathy and startle disease Newborn glycine transporter 1 (GlyT1)-knockout mice are anatomically normal but have severe motor and respiratory deficits 7 , and their phenotype resembles clinical symptoms of glycine encephalopathy (also known as non-ketotic hyperglycinaemia (see the OMIM (Online Mendelian Inheritance in Man) database entry number: 605899) 144 . These mice also die during the first postnatal day 7 . Glycine encephalopathy is typically caused by defects in components of the mitochondrial glycine cleavage system, which degrades excess glycine 4, 145 . In typical cases with early neonatal onset, affected infants experience lethargy, feeding difficulties, weak muscle tone (hypotonia), abnormal jerking movements and life-threatening problems with breathing. Convulsive seizures may also develop within a few days after birth. One-third of patients die within the first year of life, many in the neonatal period. Those who survive can live for many years but suffer from varying degrees of intellectual disability, having an average developmental age of 3-6 months, as well as intractable seizures 145, 146 . There are rare reports of individuals with glycine encephalopathy who have normal activity of the glycine cleavage system in the liver and brain, but defective central nervous system (CNS) glycine transport in post-mortem tissue 145, 147 . Mutations in GlyT1 (encoded by SLC6A9) could underlie glycine encephalopathy in these cases, as the loss of glial GlyT1 uptake would be expected to elevate glycine levels in the cerebrospinal fluid (CSF), whereas loss of GlyT1 from peripheral sites, including the liver 148 , could also lead to elevated serum glycine levels.
Startle disease (also known as hyperekplexia) is a rare genetic disorder characterized by noise-or touch-induced seizures that cause muscular hypertonia in neonates. Startle disease is associated with difficulties with swallowing and weaning and, in rare cases, infant death due to apnoea episodes, aspiration pneumonia, sinus node paucity or severe bradycardia 4 . This disorder is typically treated using the benzodiazepine clonazepam, which potentiates inhibitory GABA A (γ-aminobutyric acid type A) receptor function. In recent years it has become clear that startle disease is likely to be a glycinergic synaptopathy 13, 14, [149] [150] [151] [152] [153] . Startle disease mutations either disrupt the function of the postsynaptic glycine receptor α1 and β subunits (GlyRα1 and GlyRβ) [149] [150] [151] [152] or they disrupt presynaptic glycine uptake. Mutations in GlyT2 (encoded by SLC6A5) in startle disease are typically loss-of-function changes that disrupt transporter membrane trafficking or sodium-, chloride-or glycine-binding sites 13, 14, 153 . Genotype-phenotype analyses revealed that individuals with GlyT2 defects also had high rates of recurrent neonatal apnoeas, learning difficulties and developmental delays. Unique GlyT2 mutations have also been discovered in cattle and dogs, causing startle disorders with early neonatal lethality 154, 155 . This is consistent with the severe phenotype of Slc6a5-knockout mice, which gain weight slowly and die prematurely at the end of the second postnatal week and have a complex phenotype involving spasticity, rigid muscle tone, strong spontaneous tremors, hind feet clasping and an impaired righting reflex 8 . It is noteworthy that GlyT2 defects appear to be more severe in animals than in humans. This could affect behavioural readouts from animal models that are used during drug development. 
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Telencephalon
The largest and most highly developed part of the human brain that is involved in many higher brain functions including intelligence, personality and interpretation of sensory information; often referred to as the cerebrum or cerebral cortex in the literature.
Nucleus accumbens
The main component of the ventral (or limbic) striatum that receives ascending dopaminergic innervation and limbic glutamatergic inputs, and is involved in reward, motivation and attention.
suggesting that the anti-schizophrenia potential of GlyT1 inhibition could also depend on mechanisms other than NMDA receptor augmentation 27 . First, latent inhibition -a form of selective attention that is linked to the manifestation of positive symptoms -is robustly enhanced in Glyt1 fl/fl :CamKIIα-Cre
. This effect is also seen following systemic GlyT1 inhibition by SSR504734 and SSR103800 (REFS 31, 32) , and is also produced by all anti-psychotic drugs. These drugs include dopamine D 2 receptor antagonists that are only effective against positive symptoms 33, 34 , which is consistent with the link between the hyperfunction of the dopaminergic system and positive symptoms. However, this phenotype is not present in conditional knockout mice in which GlyT1 deletion is restricted to the telencephalon (thus GlyT1 is still expressed in the striatum). The effects on latent inhibition can be mimicked by virus-mediated deletion of striatal GlyT1 alone 35 , which suggests that the balance between cortical glutamatergic and mesolimbic dopaminergic signals converging on the nucleus accumbens is tipped in favour of the former. This is probably due to the augmentation of NMDA receptor signals originating from temporal limbic areas; these signals are crucial during learning to divert attention away from irrelevant events 36 . The presence of such an indirect suppression of mesolimbic dopaminergic signalling is further supported by studies showing that conditional genetic disruptions of GlyT1 that enhance latent inhibition also confer resistance to the motor-stimulating effects of amphetamine, a dopamine-releasing psychostimulant 11, 35 . The latter effect is also produced by the selective GlyT1 inhibitors Org 24461 (REF. 37 ) and bitopertin 38 , but surprisingly not by SSR504734. Although SSR504734 enhanced latent inhibition 31 , it potentiated (rather than suppressed) the motor response to amphetamine 39, 40 and potentiated the release of dopamine in the nucleus accumbens induced by electrical stimulation of the amygdala 41 . These dopamine-enhancing effects could result from increased glycinergic inhibition in the nucleus accumbens 42 (see below), and the relevance of the dopamineenhancing effects of SSR504734 to cognitive dysfunction in working memory and attention 43 deserves further exploration. Weakened tonic inhibition of dopaminergic release in the striatum and prefrontal cortex by GlyT1 inhibition 44 may contribute to the alleviation of negative and cognitive symptoms (in particular, working memory), especially when GlyT1 inhibitors are administered as adjuvants to D 2 receptor-blocking antipsychotics. There have been concerns that interventions to enhance 
Glyt1
fl/fl
Mice in which expression of the glycine transporter 1 gene (Glyt1; also known as Slc6a9) in the dorsal telencephalon is disrupted so that all cells in the cerebral cortex including the limbic cortices (the hippocampus and amygdala) lack GlyT1, but GlyT1 expression is retained in the striatum.
Pavlovian fear conditioning
A behavioural paradigm in which organisms learn to anticipate an aversive event by learning to associate the aversive stimulus (for example, an electrical shock) with a neutral stimulus (for example, a tone), which results in the expression of fear responses (for example, freezing or immobility) to the originally neutral stimulus.
Porsolt forced swim test
A rodent test that is used for determining the effects of antidepressant drugs. Such drugs can increase the length of time before a rodent gives up swimming or struggling and begins to float when left in a cylinder of water without any possibility of escaping.
Prepulse inhibition
A cross-species translational paradigm that is sensitive to an early attentional deficit in schizophrenia, which measures the inhibition of a startle response to an intense acoustic stimulus (that is, a pulse) induced by a weak non-startling stimulus (that is, a prepulse).
mesolimbic dopamine release could exacerbate positive symptoms; however, these have not been borne out in clinical trials, except when GlyT1 inhibition is specifically combined with clozapine 45 . Second, the promnesic effect of GlyT1 inhibition or GlyT1 disruption that is most relevant to reversing the cognitive deficits in schizophrenia -namely, improved working memory and short-term memory -is seen following systemic pharmacological inhibition of GlyT1. SSR504734 enhanced working memory performance in wild-type mice when retention demand was high 46 . Another GlyT1 inhibitor, PF-03463275, reversed ketamine-induced working memory deficits in non-human primates even though it had limited efficacy in monkeys that were not pretreated with ketamine 47 . The short-term memory deficit induced by phencyclidine was also blocked by SSR103800 (REF. 48 ).
These promnesic effects might be attributed at least partly to the positive effects of glycine and GlyT1 inhibitors on neural plasticity, including the induction of long-term potentiation (LTP), which has been demonstrated in hippocampal slices [49] [50] [51] . However, a comparable phenotype of enhanced working memory has only been clearly seen in one of the conditional knockout mutant mouse strains, Glyt1 :CamKIIα-Cre +/-mice) did not enhance working memory 52 despite the presence of a stronger baseline NMDA-mediated current (but not an AMPA-mediated current) 11 . We concluded that this discrepancy points to the importance of inhibiting GlyT1 expressed by astrocytes in the cortex 27 . Therefore, the concomitant facilitation of cortical inhibitory glycinergic neurotransmission that is expected to result from astrocytic GlyT1 deletion or inhibition should also be considered. Although the effects of glycinergic modulation on cognitive functions are not well understood, the inhibition of glycinergic neurotransmission can readily influence network activity in the hippocampus and entorhinal cortex via direct inhibition of principal neurons or via cross-inhibition with GABA (γ-aminobutyric acid)-ergic activity
. Hence, although current preclinical data are supportive of a link between glycine reuptake via GlyT1 and memory processing, it remains difficult to predict the specificity and scope of the promnesic effects produced by GlyT1 inhibition. These promnesic effects include object recognition memory 12,53 , Pavlovian fear conditioning 54 , social recognition memory 39, 55 and reversal learning 56 , all of which have varying degrees of relevance to the cognitive symptoms of schizophrenia and dissociable neural substrates.
Moreover, one cannot ignore the presence of several compensatory mechanisms that keep NMDA receptor activity in check 29, 30 as they have not been fully investigated in the two conditional GlyT1-knockout mouse lines mentioned above. Glycine-primed endocytosis of NMDA receptors 57 is thought to limit the efficacy of pharmacological GlyT1 inhibition in enhancing LTP at high doses 29 . It is probable that, in addition to the compensatory alterations in the recruitment of different NMDA receptor subtypes that may take place in different knockout models 30 , such a self-limiting mechanism could determine whether the phenotypes may diverge and therefore explain the lack of consistent promnesic phenotypes across genetic models 27 . Third, there are limited preclinical data to support the notion that GlyT1 inhibition is beneficial in depressivelike negative symptoms in schizophrenia, such as avolition and lack of affects. SSR504734 protected against depression in the chronic mild stress model of depression 39 , whereas SSR103800 produced a clear dose-dependent effect in the Porsolt forced swim test of anti-depressant effect in rats 48 . However, the mechanisms underlying these effects are unclear. Because these preclinical models cannot distinguish between the depression that is observed in patients with schizophrenia and that seen in patients with clinical depression (that is, unipolar and manic depression), these findings suggest that GlyTs and glycinergic mechanisms might have the potential to augment existing drug therapies (such as tricyclic antidepressants, selective serotonin reuptake inhibitors and lithium) that are currently used to treat patients with depression
. Although no comparable data have been reported in any current transgenic mouse models, Glyt1 fl/fl :CamKIIα-Cre +/− mice appeared to be more adaptive to changing environmental demands in purposeful behaviour 56 . This effect was also seen following SSR504734 treatment in wild-type mice 58 , which suggests that GlyT1 inhibitors could have efficacy against cognitive inflexibility and stereotypy in patients with schizophrenia.
Last, inconsistent outcomes across different genetic models 28, 59 and between different GlyT1 inhibitors were observed following the screening of several inhibitors using the prepulse inhibition (PPI) test, which is a highthroughput translational test that taxes the early sensory filtering process. Results obtained using N-methylglycine (also known as sarcosine) and N[3-(4ʹ-fluorophenyl)-3-(4ʹ-phenylphenoxy)propyl]sarcosine (NFPS; also known as ALX 5407) lack consistency across studies [60] [61] [62] . Hence, although other synthetic drugs such as (S)-13h, Roche-7 (REF. 60 ) and Org 24598 (REF. 63 ) have shown antipsychotic potential in this test, the robustness of these initial results needs to be further validated.
Importantly, a study comparing four PPI-enhancing GlyT1 inhibitors 60 suggested that a short residence time (that is, fast dissociation kinetics) may allow the identification of efficacious compounds or specific doses of a given compound that are free from notable motor and respiratory side effects, even though a long residence time does not necessarily predict the presence of respiratory distress. Both side effects are attributed primarily to increased neuronal inhibition that results from the activation of glycine receptors, and they may become apparent with sufficiently high levels of GlyT1 inhibition.
To summarize, GlyT1 inhibition is probably efficacious against several schizophrenia symptoms via its dissociable effects on separate neurotransmitter systems (glutamate, glycine and dopamine) and neural circuits (cortical versus striatal; see FIG. 3 [64] [65] [66] . Furthermore, the differential physiological impact of GlyT1 inhibition between intra-and extrasynaptic compartments must be taken into consideration in the design of GlyT1 inhibitors with new chemical structures. Marked differences in the baseline glycine concentration exist between compartments 67 , and the co-agonistic action of glycine (as opposed to d-serine) also appears to be more relevant to extrasynpatic NMDA receptors 68 .
Clinical studies. Early proof-of-principle clinical investigations using the naturally occurring GlyT1 inhibitor sarcosine and readily available agonists (glycine, d-serine and d-alanine) or the partial agonist (d-cycloserine) at the glycine-B binding site spearheaded the notion that the glycine-B site and GlyT1 are feasible targets for adjuvant treatment in schizophrenia. Clinical trials that use an adjunctive design are the endorsed approach by the US Food and Drug Administration for the evaluation of drugs that target negative and cognitive symptoms in schizophrenia 69 . Approximately 30 studies that have used this design have been extensively reviewed and subjected to meta-analyses 19, 45, 70, 71 , which addressed relevant issues such as the most appropriate compound, the formulation of the drug and its tolerability levels, the patient populations studied and the properties and dose of the baseline antipsychotic treatment.
Box 2 | Anti-epileptic potential of GlyT1 inhibition
Inhibition of glycinergic neurotransmission is an alternative strategy for controlling seizures in the 30-40% of patients with epilepsy who remain resistant to current pharmacotherapy that is designed to enhance GABA (γ-aminobutyric acid)-ergic neuronal inhibition (for example, phenobarbital and carbamazepine) or to reduce electrical conductance in neurons (for example, carbamazepine and phenytoin) 156 . Systemically administered glycine has anti-epileptic effects in rodent models and it complements the suppression of seizures by GABA A (GABA type A) receptor agonists [157] [158] [159] . Conversely, competitive inhibition of glycinergic neurotransmission by strychnine can induce convulsions 160 . The anti-epileptic effect of glycine is commonly attributed to an inhibitory regulation of neuronal excitability in the hippocampus 161 through the activation of synaptic 162 and extrasynaptic glycine receptors 163 . Local application of GlyT1 inhibitors (such as NFPS (N[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy) propyl]sarcosine) or sarcosine) can similarly increase the activation of glycine receptors by reducing the reuptake of synaptic glycine via astrocytic glycine transporter 1 (GlyT1). This thereby suppresses excitability in the hippocampus 164 . Systemic administration of sarcosine delays the onset and shortens the duration of pentylenetetrazol-induced seizures 164, 165 , whereas NFPS, SSR504734, Lu AA21279, Org 25935, SB-710622 and GSK931145 all raise the seizure threshold in the maximal electroshock seizure test in rats 166 . However, the potentiation of glycinergic inhibition alone cannot explain the efficacy of GlyT1 inhibition in these preclinical tests. d-serine and d-cycloserine bind selectively to the glycine-B site with little affinity for the glycine-A site, yet both compounds can elevate the seizure threshold [166] [167] [168] [169] . This may involve negative feedback mechanisms between excitatory pyramidal neurons and inhibitory interneurons, whereby stimulation of NMDA (N-methyl-d-aspartate) receptors enhances the GABA-mediated inhibition of hippocampal pyramidal cells 170 . However, GlyT1 inhibition may activate parallel mechanisms that have counterproductive potential (see the figure) . Indeed, glycine is elevated in human epileptogenic foci 171 . First, enhanced glycine-B site occupancy can potentiate NMDA receptor excitability 164 and contribute to the initiation and propagation of epileptic seizures 160, 172 , which underlies the efficacy of glycine-B site blockade in suppressing seizures in several animal models 173, 174 . Second, sustained stimulation of NMDA receptors disrupts GABAergic activity, which leads to disinhibition of neuronal excitability that begets and sustains further seizures 175 . The link between prolonged depolarization via NMDA receptors and epilepsy-aphasia spectrum disorders has been unequivocally demonstrated following the discovery of mutations in the NMDA receptor GluN2A subunit gene GRIN2A [176] [177] [178] [179] . Third, cross-inhibition between glycine receptors and GABA A receptors 180 in the hippocampus and entorhinal cortex 181, 182 may allow the suppression of GABAergic inhibition via glycine receptor activation. Any attempt to translate the control of brain glycine homeostasis into clinically effective anti-epileptic tools must consider the complex interplay among glycinergic, GABAergic, NMDA and AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor mechanisms, especially within the context of polypharmacy in epilepsy 183 
.
The results from these studies were generally positive 72 , and one multicentre study stands out in which negative symptoms were notably improved in inpatients but not in outpatients, for reasons that remain unclear 73 . Adjuvant glycine is particularly effective in reducing negative symptoms in patients with low serum glycine levels, in whom there is more scope for elevating the occupancy of the glycine-B site 74 . However, very high daily doses of glycine are required owing to its poor brain penetration and high peripheral metabolism, and this makes GlyT1 inhibition an attractive alternative, as demonstrated by the comparable efficacy of sarcosine [75] [76] [77] [78] . Two clinical issues related to GlyT1 inhibition therapy in schizophrenia may deserve special attention.
First, the efficacy of glycine is contingent upon the concurrent use of an antipsychotic medication other than clozapine 45, 79 . This raises the interesting possibility that clozapine may already increase synaptic glycine levels through as yet unknown mechanisms 80 . Indeed, combining GlyT1 inhibitors with clozapine might actually worsen positive symptoms 45 . This undesirable drugdrug interaction might be linked to specific synergistic interactions between GlyT1 inhibition and dopamine neurotransmission, as was demonstrated in preclinical models 40 . One consequence of this unwanted interaction with clozapine is that all Phase III clinical trials of bitopertin have excluded patients who receive background clozapine therapy. This also implies that Phase III trials of bitopertin did not include patients receiving clozapine in the placebo arm of the trial. Therefore, these late-stage trials cannot determine whether a combined therapy (of bitopertin and a non-clozapine antipsychotic) will be more effective than maintenance therapy on clozapine (that is, placebo and clozapine) against negative symptoms. A head-to-head comparison to determine this is particularly important given that clozapine remains one of the most effective antipsychotics currently used to treat negative symptoms, and its efficacy can vary between studies 81 . Second, adjunctive glycine, d-serine and sarcosine therapy can improve both positive symptoms and negative symptoms 45 . This begs the question as to whether the demonstrated reduction in negative symptoms might be secondary to better control of positive symptoms. This observation is corroborated by results obtained from specific models of GlyT1 disruption, which show suppression of dopamine overactivity 11 . Alternatively, GlyT1 inhibition might indeed confer broad-spectrum benefits on both positive and negative symptoms. To properly evaluate
Box 3 | Affective disorders: obsessive compulsive disorder and depression
Hoffman-La Roche has recently initiated a Phase II efficacy and safety trial of bitopertin in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with treatment-resistant obsessive-compulsive disorder (OCD) (ClinicalTrials.gov identifier: NCT01674361). This is a timely follow-up study to two earlier small-scale studies suggesting that adjuvant glycine or sarcosine in combination with SSRIs might enhance the control of OCD symptoms, and that sarcosine might be effective even when administered alone 184, 185 . The therapeutic mechanism probably involves the augmentation of NMDA (N-methyl-d-aspartate) receptor function rather than the potentiation of glycinergic neurotransmission. First, by increasing binding to the glycine-B site of the NMDA receptor, glycine transporter 1 (GlyT1) inhibition might reverse the glutamate hypofunction in frontal cortices that is implicated in the pathogenesis of OCD 186, 187 . Second, when given as an adjuvant medication, the therapeutic efficacy observed in some studies may be further derived from the augmentation of ongoing behavioural cognitive therapy. This is the common interpretation of the efficacy of d-cycloserine -a partial agonist at the glycine-B sitein patients with OCD receiving so-called behavioural exposure therapy that is designed to weaken the link between obsession-related stimuli (for example, public restrooms) and feared outcomes (for example, contamination) 188, 189 . It is noteworthy that positive augmentation by d-cycloserine has also been reported in phobia 190, 191 , panic disorder 192 and social anxiety 193, 194 . However, augmentation of behavioural therapy by glycine-B site activation cannot explain the reported efficacy of sarcosine in patients not receiving behavioural therapy in the treatment period 185 . Indeed, the synergism with behavioural therapy may be unique to d-cycloserine because a recent trial showed that the GlyT1 inhibitor Org 25935 did not improve the outcome of cognitive behavioural therapy for panic disorder 195 . Studies in animal models have indicated that SSR504734 (REF. 39 ) and sarcosine 196 might have some anxiolytic properties. These findings are typically linked to their potential benefit on the broader spectrum of affective symptoms that include depressive symptoms. SSR504734 conferred protective effects in the chronic mild stress model of depression 39 . Another competitive inhibitor, SSR103800, had a clear dose-dependent effect in the Porsolt forced swim test 48 . Similar preclinical and clinical indications have been identified with sarcosine in a recent study 196 , which reported that sarcosine monotherapy was superior to the SSRI citalopram on several depressive symptom scales as well as remission rate. This is consistent with the improvement in depressive symptoms observed following treatment with d-cycloserine 197 or GLYX-13 (another partial agonist at the glycine-B site) 198 , which indicates that increased binding of glycine to the glycine-B site may represent a new antidepressant mechanism that can be achieved by GlyT1 inhibition 196 . This mechanism might preferentially involve synaptic NMDA receptors, whereas the antidepressant effects of ketamine are attributed to the blockade of extrasynaptic NMDA receptors 199 . The distinction between synaptic and extrasynaptic NMDA receptors might also be relevant to the complex modulation of GlyT1 and GlyT2 activities by the antidepressant drugs amoxapine 107 and lithium 200 , and it may also be important for the interaction of glycine-B site ligands with tricyclic antidepressants and SSRIs 201 . Knockout mouse models did not reveal any consistent anxiolytic-like or antidepressant-like phenotype 27 , except for reduced fear in response to a novel environment in Glyt1 +/− mice 202 this, double-blind monotherapy trials (for example, the current d-serine monotherapy trial; ClinicalTrials.gov identifier: NCT00816894) as well as head-to-head comparisons between mono-and polytherapy would be needed 69 . To date, all existing monotherapy trials have been uncontrolled and of a small scale 79, 82, 83 .
Bitopertin. Bitopertin is a potent, non-sarcosine-based, non-competitive GlyT1 inhibitor that has a higher than 1,000-fold selectivity for human GlyT1 versus GlyT2 (REF. 84 ). Besides bitopertin, seven other synthetic GlyT1-selective inhibitors (Org 25935, PF-03463275, SSR504734, SSR103800, DCCCyB, JNJ17305600 and AMG 747) that are based on distinct chemical scaffolds have been evaluated in Phase I and/or Phase II clinical trials (publicly accessible information is summarized in TABLE 1). However, none of these other candidate GlyT1 inhibitors is being further pursued (for undisclosed reasons) as an antipsychotic drug.
At present, multicentre Phase III clinical trials of bitopertin are in progress (TABLE 1) . A clearer picture of the clinical efficacy of bitopertin will emerge when the results of these trials are published (the earliest completion date is anticipated to be 2014). Based on disclosed data from Phase IIb proof-of-concept studies, 8-week adjunctive treatment with bitopertin at a dose of 10-30 mg per kg combined with ongoing antipsychotic treatment (excluding clozapine) improved the negative symptom factor score by 25% compared to the 19% improvement observed in patients receiving placebo add-on 85 . At the lower dose of 10 mg per kg, bitopertin add-on treatment also improved personal and social 5 ). This may have an impact on the negative symptoms of schizophrenia such as apathy and reduced motivation. d | The disinhibition of the VTA may also strengthen dopaminergic signals to the prefrontal cortex (PFC) and, as such, could address the underactivity of prefrontal cortices in schizophrenia (the so-called 'hypofrontality' syndrome) that are responsible for crucial cognitive and negative symptoms including poor working memory, executive function, behavioural inflexibility and dysfunction in attention.
performance scores by ~17% compared to ~12% with an add-on placebo (see pages 76-77 of the Roche late-stage pipeline update (December 2010) on the Roche website).
The fact that it took 8 weeks to achieve these clinical improvements (with an effect size of 0.37-0.40 and with marginal statistical significance) has led to some concern over the robustness of the outcomes 71 . A comparable reduction in positive symptoms was also observed, which was similar to the reduction in positive symptoms seen in clinical trials with adjunctive glycine and sarcosine. Adverse nervous and musculoskeletal effects seen with the higher dose of bitopertin (60 mg Data obtained from binding assays of bitopertin indicated that the optimal dosage of 10-30 mg per kg, which was well tolerated in humans, corresponds to 50% target occupancy; this is comparable to the target occupancy associated with maximal effective doses in rat and monkey models (see page 70 of the Roche late-stage pipeline update (December 2010) on the Roche website). The 50% target occupancy is in line with the indication that stronger genetic knockout of GlyT1 seems to be associated with fewer anti-psychotic phenotypes than more extensive genetic knockout 27 . This raises the possibility that the priming of NMDA receptor internalization by excessive stimulation of the glycine-B site may limit or even reverse the intended augmentation of NMDA receptor function if the number of functional NMDA receptors begins to decrease 29, 57 . Nonetheless, the empirically determined 50% target occupancy will continue to guide the clinical development of bitopertin. Although achieving this through dose titration alone might prove to be difficult as the occupancyversus-dosage curve of bitopertin remains relatively steep near the desired range (see page 74 of the Roche late-stage pipeline update (December 2010) on the Roche website), individual patient titration with the assistance of PET imaging 86 may be an option. Careful consideration of the most appropriate dose will be important when taking into account the potential application of GlyT1 inhibition therapy in other neuropsychiatric conditions (BOXES 2-4). Indeed, Roche is directly translating the dose range (10-30 mg per kg) that is effective in patients with schizophrenia to the proof-of-principle study of bitopertin (ClinicalTrials.gov identifier: NCT0167436) in patients with obsessive-compulsive disorder
GlyT1 in alcohol dependence therapy
The addictive potential of drugs of abuse, including alcohol and cocaine, depends on the rewarding effects induced by such drugs, which not only reinforce drug intake but also facilitate the association between events linked to the consumption of drugs and drug-seeking behaviour. The reward signal induced by drugs of abuse in the brain corresponds to an increase in dopamine release in the nucleus accumbens, which is mediated by the direct neuronal projection from the ventral tegmental area. It has been suggested that the enhancement of glycinergic inhibition, induced by GlyT1 inhibition, can dampen the rewarding effects of alcohol and thus facilitate alcohol detoxification and reduce relapse drinking in rats 42, 87, 88 . In addition, data from monkeys and rats suggest that stimulation of the glycine-B site on the NMDA receptor, which can also be induced by GlyT1 inhibition, facilitates extinction training, a behavioural procedure that is designed to weaken the link between drug-associated cues and drug rewards that drives drug-seeking behaviour [89] [90] [91] . A greater and more persistent reduction in the association between drug-associated cues and drug rewards, resulting from GlyT1 inhibition in combination with behavioural cessation therapy, is expected to reduce the probability of relapse and support long-term abstinence from potential drugs of abuse, including alcohol, cocaine and nicotine. Hence, separate suggestions have been made regarding the relevance of GlyT1 inhibition to the distinct mechanisms underlying both pathological alcohol consumption and relapse drinking.
The potential synergism between extinction learning and GlyT1 inhibition is also relevant to the extension of GlyT1 inhibition therapy for the treatment of obsessivecompulsive disorder and related anxiety disorders
. In patients with these affective disorders, complementary GlyT1 inhibition may aid in the suppression of unwanted behaviour and thoughts.
Studies in rats have shown that two sarcosine-based non-competitive GlyT1-selective inhibitors, Org 25935 and Org 24598, are both effective in reducing relapse-like compulsive drinking 92 and alcohol preference 42, 87 . So far, competitive GlyT1 inhibitors have not been evaluated in animal models of alcoholism. The anti-alcohol efficacy of Org 25935 in rats was largely independent of baseline alcohol preference 87, 93 , which might stem from the noncompetitive binding mode of this inhibitor, as it should produce elevations in glycine levels that are independent of variations in extracellular glycine levels. However, the initial attempt to translate Org 25935 to patients was aborted before completion; the Phase II efficacy and safety trial for relapse prevention in individuals with alcohol dependence was stopped mid-way owing to an initial disappointing outcome 94 . Mechanistically, the efficacy of Org 25935 in rodents has been localized to its effects within the nucleus accumbens. Local infusion of Org 25935 into the nucleus accumbens is sufficient to attenuate alcohol-induced dopamine release 42, 93 . This effect can be explained by the Org 25935-induced local increase in extracellular glycine levels, because the perfusion of glycine directly into the nucleus accumbens similarly decreased alcohol preference and intake 87 . Furthermore, the anti-alcohol effects of Org 25935 or glycine can be blocked by the local application of the glycine receptor antagonist strychnine, which suggests that the activation of inhibitory glycine receptors within the nucleus accumbens is crucial. Increasing glycinergic inhibition in the nucleus accumbens suppresses the dopamine-dependent hedonic value of alcohol and thereby reduces alcohol consumption. Conversely, blockade of glycinergic activity within the nucleus accumbens by strychnine increases alcohol consumption 95 .
Complete Freund's adjuvant
A water-in-oil emulsion that contains heat-killed mycobacteria or mycobacterial cell wall components, and is used to induce an inflammatory response and pain in animal models.
A mechanistic account for the inverse relationship between glycinergic inhibitory activity in the nucleus accumbens and alcohol consumption has been developed 88 . Essentially, glycine or GlyT1 inhibitors drive the release of dopamine by potentiating glycinergic inhibition on GABAergic cells in the nucleus accumbens, which then exert negative feedback control on dopamine-releasing cells in the ventral tegmental area (FIG. 4) . While GlyT1 inhibitors potentiate glycinergic inhibition by reducing the removal of synaptic glycine, alcohol achieves the same end effect by increasing the affinity of glycine for its receptor 96 . The physiological end point of GlyT1 inhibition therapy is to limit the reinforcing effect of alcohol. In this respect, the effects of GlyT1 inhibition are not dissimilar to that of nalmefene, an opioid receptor ligand that is approved by the European Medicines Agency for the treatment of alcohol dependence. Nalmefene elevates mesolimbic dopamine activity through partial antagonism at κ-opioid receptors. Similar to the actions of glycine activation produced in the nucleus accumbens, nalmefene suppresses the inhibitory feedback pathway on dopaminergic neurons in the ventral tegmental area 97 . Furthermore, nalmefene normalizes the pathological compulsion to consume alcohol that is mediated by increased κ-opioid receptor activity in the brain of individuals suffering from alcohol addiction 97, 98 . The possibility that GlyT1 inhibitors and nalmefene might complement each other may deserve consideration, especially because nalmefene therapy can be prescribed as and when needed 99 .This approach should further minimize unwanted development of drug tolerance, which is a major limitation of another antialcohol therapy: acamprosate (also known as N-acetyl homotaurine; an NMDA receptor antagonist). Indeed, studies in animal models have shown that nalmefene as well as the GlyT1 inhibitors Org 25935 and Org 24598 are less susceptible to the development of drug tolerance 100, 101 . Acamprosate is thought to impede the development of the persistent NMDA receptor-dependent neuroplastic changes in the ventral tegmental area that drive alcohol-craving and alcohol-seeking behaviour, which precipitates relapses [102] [103] [104] . Selective deletion of NMDA receptors from ventral tegmental dopaminergic neurons in mice can prevent relapse-like behaviours induced by cocaine 105 , and a similar effect can be induced by the GlyT1 inhibitors RO4543338 (REF. 90 ) and Org 24598 (REF. 91 ). The long-term anti-relapse effect of Org 25935 was accompanied by normalization in the levels of expression of genes associated with glutamatergic and glycinergic signalling, which remained normalized well into treatment-free periods 92 . This suggests that the anti-relapse potential of GlyT1 inhibition may involve additional modifications to NMDA receptor density 57 or composition 30 that limit the NMDA receptor-mediated plasticity induced by alcohol consumption.
In this context, it is notable that the effective antialcohol doses of Org 25935 are associated with a 50-80% increase in extracellular glycine levels in the striatum of rats 93 , which are probably sufficient to trigger NMDA receptor internalization 57 . Although speculative, if a similar magnitude of glycine elevation was present in the ventral tegmental area, it might lead to a reduction in the levels of NMDA receptors and contribute to the suppression of alcohol relapse.
The multiple actions of GlyT1 on separate loci within the brain circuits that are implicated in addiction behaviour offer extensive opportunities for development and refinement. Despite the initial disappointment with Org 25935 (REF. 94 ), clinical trials with newer compounds should be encouraged.
Pain control by GlyT1 and GlyT2 inhibition
Data from current preclinical models of pain suggest that the inhibition of GlyT1 and/or GlyT2 may hold promise for the improved management of neuropathic pain with fewer side effects than current treatments such as tricyclic antidepressants, which have broad pharmacological actions 106 . Incidentally, the pharmacological actions of tricyclic antidepressants may partly involve the inhibition of GlyTs 107 . Inhibitors of GlyT1 and GlyT2 produce robust nociceptive effects in several animal models of pain, including the sciatic nerve injury model 108 , the complete Freund's adjuvant-induced peripheral inflammation model 109 , the formalin-induced pain model 108 , acetic acid-induced writhing syndrome 110 and intravesical resiniferatoxin-induced pain 111 . The complementary regulation of the processing of pain signals and nociceptive sensation by GlyT1 and GlyT2 in the spinal cord have been comprehensively reviewed in the literature 110 . GlyT1 and GlyT2 tightly regulate the convergence of inhibitory glycinergic
Box 4 | Glycinergic transmission and inflammatory pain
The glycine receptor α3 subunit (GlyRα3; encoded by GLRA3) has a selective distribution in the outer laminae of the spinal cord dorsal horn, which has led to studies of Glra3-knockout mice in models of inflammatory and chronic pain [205] [206] [207] [208] . Glra3-knockout mice had reduced central pain sensitization 205 and reduced levels of writhing responses in a model of inflammatory hyperalgesia. However, they had no changes in formalin-induced pain and developed normal thermal hyperalgesia and tactile allodynia 206 . Moreover, Glra3-knockout mice had normal sensitivity to neuropathic pain, visceral pain and chemically induced pain 207 , as well as to pain associated with rheumatoid arthritis and osteoarthrosis 208 . Further investigation revealed that the molecular pathway underlying central inflammatory pain sensitization involves the activation of the prostaglandin E2 receptor (PTGER2), which then induces protein kinase A (PKA)-mediated phosphorylation of GlyRα3. This phosphorylation depresses glycine-activated inhibitory chloride currents. Thus, the lack of central pain sensitization or peripheral inflammation in Glra3-knockout mice is due to the removal of the downstream substrate (GlyRα3) of prostaglandin E signalling via the cognate receptor PTGER2. This mechanism indicates that it may be possible to reduce inflammatory pain either by allosterically potentiating GlyRα3 activity or by potentiating the activity of GlyRα1, which colocalizes with GlyRα3 at dorsal horn synapses 205 . This could restore the efficacy of glycinergic inhibition and thereby reduce central pain sensitization.
GlyRα3 has also been implicated in a model of tactile allodynia 109, 209 in a pathway involving glutamate, nitric oxide, cyclic GMP and PKG. In addition, this receptor has been implicated in the response to the acute thermal pain reflex 210 , which is consistent with the proposal that spinal pathways are crucial for this behaviour. Moreover, this study suggested that the analgesic effects of certain cannabinoids are directly mediated by GlyRα3 rather than the G protein-coupled cannabinoid 1 receptor and cannabinoid 2 receptor. neurotransmission and excitatory glutamatergic neurotransmission in the superficial dorsal horn, which is where pain signals that project to the thalamus are processed and gated (FIG. 5) . Neural inhibition that is mediated by glycine receptors containing the α3 subunit (GlyRα3; encoded by GLRA3) can suppress the transmission of pain signals to the brain (BOX 4), whereas neural excitation mediated by NMDA receptor activation potentiates the pain signals and sensitizes nociception. Augmenting glycinergic inhibition in the dorsal horn should therefore provide pain relief, as evidenced by the analgesic effects of intracerebroventricular or intrathecal injection of glycine in mice 112 . This can similarly be achieved by blocking glycine reuptake from glycinergic synapses (FIG. 5) .
The anti-allodynic action of the GlyT1 inhibitors Org 25935 and sarcosine is highly effective in rodent models regardless of the route of drug delivery (that is, oral, intravenous or intrathecal administration). The analgesic effects lasted for several hours following a single dose, exceeding the anti-nociceptive effects produced by gabapentin 109 . Consistent with the analgesic effects seen in these models, the anti-nociceptive action of the non-competitive GlyT1 inhibitors Org 25935, sarcosine 109 and NFPS 108 depends on the stimulation of GlyRα3 in the spinal cord. Intrathecal injection of strychnine or knockdown of GlyRα3 effectively nullifies the anti-nociceptive effects of these compounds but does not potentiate pain 109 . These findings dispel concerns that a concomitant increase in the binding of glycine to the glycine-B site (on NMDA receptors), induced by GlyT1 inhibition, may potentiate the transduction of pain signals. Instead, prolonged occupation of the glycine-B site might induce NMDA receptor internalization 57 and therefore reduce neuronal excitation that might otherwise amplify pain signals. However, this mechanism may 87, 101 can therefore dampen the reward signals associated with alcohol consumption because alcohol is thought to activate the same mesolimbic dopamine pathway via a similar glycinergic mechanism 88 . GlyT1, glycine transporter 1. Instead, clinical evidence suggests that pain suppression may be achieved by the blockade (instead of activation) of the glycine-B site. The glycine-B site antagonist GV196771 reduced the area of the skin that was afflicted by static allodynia in patients with neuropathic pain after 7 days of treatment, even though self-reported pain intensity remained unchanged 113 . In rats, the analgesic effect of intrathecally administered glycine was also substantially enhanced by the co-administration of 2-amino-5-phosphonopentanoate (AP5), a compound that blocks NMDA receptors 114 . GlyT1 blockade in specific areas of the brain (in addition to the spinal cord) may also produce analgesic effects. In a rat model of neuropathic pain, local infusion of sarcosine in the medial prefrontal cortex was sufficient to reduce pain sensitivity in the injured paw 115 . Thus, there Projection neurons located in the superficial layers of the dorsal horn, which transmit pain signals to the thalamus, are tightly regulated by the inhibition of glycinergic signalling (descending glycinergic anti-nociception) via glycine receptors containing the α3 subunit (GlyRα3). Inhibition of glycine transporter 2 (GlyT2) as well as GlyT1 potentiates the activation of glycinergic inhibitory neurotransmission by reducing the reuptake of glycine from glycinergic synapses, which further inhibits the firing of projection neurons and thereby suppresses pain; the inserts depict local glycinergic transmission in the absence (top panel) and presence (bottom panel) of glycine reuptake inhibition. Blockade of GlyT2, as shown in the bottom panel of the insert, does not seem to impair vesicular refilling of glycine at the presynaptic terminals and therefore does not limit presynaptic glycine release. Nociceptive C-and Aβ fibres stimulate the pain projection neuron and also activate glycinergic interneurons (which mediate descending noradrenaline-and serotonin-mediated anti-nociception signals) that inhibit the pain projection neuron. It is possible that the activation of glycinergic interneurons via NMDA (N-methyl-d-aspartate) receptors may be strengthened by GlyT1 inhibition, thereby providing additional inhibition of the pain signals that are destined for the brain. may be additional opportunities to interfere with the perception of pain through the inhibition of GlyT1 in the brain. Indeed, GlyT1 inhibition in the brain might even provide some relief from cognitive and non-cognitive behavioural comorbidities that are associated with hippocampal dysfunction and are common in patients with chronic pain 108, 116 . Recently, specific metabolites of the local anaesthetic lidocaine -including monoethylglycine xylidide, glycine xylidide and N-ethylglycine -were shown to inhibit GlyT1 activity, which may contribute to the anti-nociceptive effects of systemically administered lidocaine via an as yet unknown mechanism 117 . Because GlyT2-mediated glycine reuptake is thought to be essential for vesicle refilling in presynaptic glycinergic nerve terminals, inhibition of GlyT2 in the dorsal horn was initially thought to potentiate nociception. However, GlyT2-selective inhibitors such as Org 25543 and ALX 1393 have exhibited anti-nociceptive effects against acute thermal, mechanical and chemical pain 109, 118, 119 , and appear to be more effective than GlyT1 inhibitors in rodent models of urological pain 111 as well as herpetic or post-herpetic pain 120 . The efficacy of GlyT2 inhibition therefore clearly depends on the activation of glycine receptors. Very low doses of strychnine readily block the anti-allodynia effects of GlyT2 inhibitors in mice without causing motor disturbances 109 , which suggests that sensory signalling is far more sensitive to glycinergic control than motor control. Moreover, the anti-nociceptive effects produced by GlyT2 inhibitors are fast-acting and effective at low doses 110 . Doses of GlyT2 inhibitors that induce anti-nociception do not produce signs of startle disease-like behaviour. These favourable properties are attributable to the more restrictive and higher expression of GlyT2 in the dorsal horn in comparison with the more diffused distribution of GlyT1 in the spinal cord.
The therapeutic potential of GlyT2 inhibitors as indicated in preclinical models has so far not been translated to the clinic. Intrathecal administration of glycine (32 mg per day for 4 weeks) produced similar effects to placebo in a cohort of patients with complex regional pain syndrome 121 . Additional proof-of-principle studies with higher doses of glycine or potent inhibitors of GlyT1 and/or GlyT2 are warranted.
Further clinical considerations
Side effects of glycine reuptake inhibition. Both preclinical and clinical data indicate that therapeutic doses of glycine reuptake inhibitors are generally well tolerated. Early concerns of excitotoxicity resulting from the potentiation of NMDA receptor activity 122 have been largely dispelled by the clinical trials with glycine and selective GlyT1 inhibitors. Motor and respiratory side effects are primarily attributed to the sustained elevation of glycinergic inhibition 22, [123] [124] [125] and might be induced by both GlyT1 and GlyT2 inhibitors. However, such side effects are limited at therapeutic doses, as seen in animal models of pain control and in the Phase II clinical trials of bitopertin in patients with schizophrenia. Furthermore, motor and respiratory side effects should be further minimized through the use of competitive inhibitors with a low target residence time or fast dissociation kinetics 60, 126 . However, Phase II clinical trials have a limited treatment duration and additional side effects might be identified during Phase clinical III trials, in which treatment times will be extended to at least 12 months (TABLE 1) . Gastrointestinal side effects may also emerge given that GlyT1 is expressed throughout the human intestine 127 , and recurrent gastrointestinal side effects have been reported following glycine therapy 128 . Another potential concern is adverse skin reactions, because NMDA receptor stimulation can disrupt cutaneous barrier homeostasis 212 . This concern has been emphasized in a commentary on the suspended development of AMG 747 (see the BioMedTracker report on AMG 747) following the identification of unspecified safety issues in Phase II clinical trials (TABLE 1) .
Monotherapy versus adjunctive therapy. Current efforts to translate glycine reuptake inhibition therapy to the clinic typically involve administering the new drug as an adjuvant treatment to existing medications. This is the chosen approach in the ongoing clinical trials of bitopertin for schizophrenia and obsessive-compulsive disorder. Although polypharmacy is not uncommon and can be rationalized on clinical and mechanistic grounds for diseases such as epilepsy 129 and schizophrenia 130 , whether polypharmacy actually improves clinical outcomes is a contentious issue in psychiatry 131 . Nonetheless, clinical trials of single drugs, as well as clinical trials that compare monotherapy to polytherapy, should be encouraged (TABLE 1) . Results from a small-scale study suggest that GlyT1 inhibitor monotherapy can improve positive symptoms as well as negative symptoms in patients with schizophrenia 79 . This may justify the design of clinical trials of GlyT1 inhibitors as monotherapies, which -according to the US Food and Drug Administration 69 -are reserved for drugs that are anticipated to provide benefits across a board spectrum of symptoms in schizophrenia. Large-scale, double-blind, controlled trials of a monotherapy study design would clarify remaining uncertainties regarding the symptom specificity and therapeutic mechanisms of glycine reuptake inhibition therapy. Simultaneously, animal models of polypharmacy should also follow leads from clinical data to identify possible drug-drug interactions that could help distinguish between beneficial drug combinations and potentially detrimental ones 132 .
Further mechanistic considerations
Fine-tuning the inhibition of glycine reuptake. The potential of therapies based on glycine reuptake inhibition in each of the relevant disorders highlighted in this Review depends on the ability of this pharmacological approach to rebalance the neuronal signalling mediated by glycine receptors and/or NMDA receptors. The relative importance of these two signalling pathways depends on the specific pathophysiology that is involved in each disorder. Enhancing glycinergic inhibition could be beneficial in the reward pathways (for the treatment of pain), the spinal cord (for the control of alcohol addiction) and temporal cortices (for the treatment of epilepsy), whereas NMDA receptor augmentation in these areas is attributed to poorly defined or even undesirable effects for the respective clinical conditions. In schizophrenia, improvement of NMDA receptor function in the forebrain is central to the rationale of GlyT1 inhibition therapy, although the augmentation of inhibitory glycinergic mechanisms could also be relevant for improving specific symptoms.
Fine-tuning therapy to specific regions of the brain could be feasible for pain control or for the prevention of epilepsy -disorders in which local pharmacological interventions to the spinal cord or epileptic foci are feasible. But this strategy remains speculative for conditions like schizophrenia or alcohol addiction. The ability to fine-tune the dual action of glycine on glycine-A and glycine-B binding sites could therefore be crucial for maximizing the potential clinical benefits of GlyT1 inhibition.
Attempts to strike the right balance between activation of the glycine-A site or the glycine-B site through dose titration, as concluded in the Phase II clinical trials of bitopertin, is the logical first step. The reported efficacious doses of bitopertin (10-30 mg per kg) in patients translate to a 200-250% increase in striatal glycine levels in rats 38 . This is considerably higher than the effective doses of Org 25935 and Org 24598 on alcohol consumption in rats, which increased extracellular striatal glycine levels to 150-180% of controls. Interestingly, these lower levels of glycine elevation are more likely to resemble those produced by the lower dose range of bitopertin, which is currently being evaluated in Phase III trials. The eventual outcomes therefore should clarify whether the anti-schizophrenia and anti-alcohol efficacy of GlyT1 inhibition may be segregated with respect to the dose, target occupancy and/or elevation of extracellular glycine levels. Such data may be useful in screening candidate compounds given the mechanistic relevance of increasing striatal glycine levels in these clinical conditions. A potent and selective GlyT1 inhibitor -referred to as compound 62 (REF. 133 ) -could therefore be of interest, as it is highly effective in rapidly elevating striatal glycine levels in mice.
Because the level of occupancy of the glycine-A binding site on glycine receptors and the glycine-B binding site on NMDA receptors is normally regulated by neuronal and glial GlyT1, respectively, distinguishing between these two subpopulations of GlyT1 has the potential to differentially augment the activity of NMDA versus glycine receptors. Neuronal GlyT1 is co-expressed with NMDA receptors, and selective inhibition of these receptors is ideal for increasing glycine-B site occupancy and thereby the potentiation of NMDA receptor activation. By contrast, selective inhibition of astrocytic GlyT1 should preferentially strengthen glycinergic neurotransmission by impairing the reuptake of glycine that is released into glycinergic synapses. This distinction could be related to the lack of anti-schizophrenia efficacy observed when bitopertin occupied >50% of GlyT1. Above this level, the glycine-B sites in glutamatergic synapses are probably saturated such that further inhibition of neuronal GlyT1 can no longer increase NMDA receptor currents 28 . By contrast, the neuronal inhibition mediated by glycine receptors could still be further strengthened as a result of further inhibition of glial GlyT1. However, further increases in glycine concentration near NMDA receptors would stimulate compensatory receptor endocytosis 57 .
Synaptic localization of NMDA receptors.
There is evidence that glycine may preferentially modulate the activity of extrasynaptic NMDA receptors, whereas d-serine released by astrocytes and neurons is the key co-agonist for synaptic NMDA receptors 68, 134 . Furthermore, the subunit composition of NMDA receptors varies depending on their location.
Hence, manipulating the homeostasis of d-serine -for example, via the targeting of serine racemase or d-amino acid oxidase -may be more efficient than modulating glycine levels to specifically modify neurotransmission via synaptic, predominantly GluN2A-subunit-containing, NMDA receptors 2, 135 . Conversely, upregulating glycine near extrasynaptic NMDA receptors preferentially increases tonic currents mediated predominantly by GluN2B-subunit-containing receptors 68 . Regulatory proteins, such as Ala-Ser-Cys transporter 1 (ASC1; encoded by the SLC7A10 gene), that control the neuronal release of both glycine and d-serine may be particularly attractive targets for altering overall excitatory currents mediated by both synaptic and extrasynaptic NMDA receptors 136 . However, the synthesis of d-serine in neurons and astrocytes is highly sensitive to the intracellular concentration of glycine 137 , which is, in turn, regulated by the activities of GlyT1 and GlyT2. Hence, attempts to modify NMDA receptor functionality through changes to the glycine-B site occupancy must take into consideration the intricate balance and regulation of the synthesis, release and reuptake of both endogenous glycine-B site ligands -d-serine and glycine -which also differentially modify the lateral diffusion of NMDA receptors 68 . GlyT1 also has a unique interaction with NMDA autoreceptors at presynaptic terminals in the hippocampus, where GlyT1-mediated inward glycine and/or sodium currents can facilitate NMDA autoreceptor activation by overriding the magnesium block 138 . Blockade of presynaptic GlyT1 by NFPS can reduce the release of glutamate from synaptosomes isolated from the hippocampus 138 , but this may not be easily generalized to other areas of the brain because the physiological functions of NMDA autoreceptors may vary among regional neural circuits 139 . These additional considerations are highly relevant to the interpretation of findings from preclinical models that have been highlighted in this Review, and will also be important for future structure-activity relationship analyses of candidate compounds.
Conclusion
Given that therapies based on the inhibition of glycine reuptake are at an advanced clinical stage for the potential treatment of schizophrenia, the therapeutic scope of glycine reuptake inhibition will probably expand beyond the specific conditions reviewed here. Newer selective inhibitors with proven tolerability should facilitate
Epileptic foci
Localized areas of the brain where a crucial number of pathologically discharging neurons reside; these neurons have the potential to give rise to widespread brain seizures.
NMDA autoreceptors
NMDA (N-methyl-d-aspartate) receptors that are located on presynaptic nerve cell membranes. They may provide tonic facilitation of neural transmission, contribute to neural plasticity such as long-term depression or be part of a negative feedback loop to reduce glutamate release.
